Novel troponin fragmentation assay to discriminate between Takotsubo syndrome and acute myocardial infarction.

Takotsubo syndrome biomarker myocardial infarction myocardial injury troponin

Journal

European heart journal. Acute cardiovascular care
ISSN: 2048-8734
Titre abrégé: Eur Heart J Acute Cardiovasc Care
Pays: England
ID NLM: 101591369

Informations de publication

Date de publication:
18 Oct 2024
Historique:
received: 17 08 2024
revised: 24 09 2024
accepted: 17 10 2024
medline: 18 10 2024
pubmed: 18 10 2024
entrez: 18 10 2024
Statut: aheadofprint

Résumé

Cardiac troponin levels are elevated in Takotsubo syndrome (TTS) with significant overlap to acute myocardial infarction (MI). Long and intact cardiac troponin T (cTnT) forms are typical for MI. This study sought to assess whether the fragmentation composition of cTnT release in TTS differs from MI. The concentration of long molecular forms of cTnT (long cTnT) was measured with a novel upconversion luminescence immunoassay and total cTnT with a commercial high-sensitivity cTnT assay in 24 TTS patients and in 84 Type 1 MI patients. The ratio of long to total cTnT (troponin ratio) was determined as a measure of cTnT fragmentation. Troponin ratio was lower in TTS patients 0.13 [0.10-0.20] vs. 0.62 [0.29-0.96], p<0.001). In the ROC curve analyses, troponin ratio showed a better predictive power than total cTnT in discriminating TTS and MI patients (AUC 0.869 [CI95% 0.789-0.948)] vs. 0.766 [CI95% 0.677-0.855], p=0.047). When restricting the analysis to patients with total cTnT below 1200 ng/L (maximal value in TTS patients), the respective AUC values for total cTnT and troponin ratio were 0.599 (CI 95% 0.465-0.732) and 0.816 (CI95% 0.712-0.921), p =0.003). At a cutoff point of 0.12, troponin ratio correctly identified 95% of MI patients and 50% of TTS patients. In contrast to Type 1 MI, only a small fraction of circulating cTnT in TTS exists in intact or long molecular forms. This clear difference in troponin composition could be of diagnostic value when evaluating patients with cTnT elevations and suspicion of TTS. URL: https://www.clinicaltrials.gov; Unique identifier: NCT04465591.

Sections du résumé

BACKGROUND BACKGROUND
Cardiac troponin levels are elevated in Takotsubo syndrome (TTS) with significant overlap to acute myocardial infarction (MI). Long and intact cardiac troponin T (cTnT) forms are typical for MI. This study sought to assess whether the fragmentation composition of cTnT release in TTS differs from MI.
METHODS METHODS
The concentration of long molecular forms of cTnT (long cTnT) was measured with a novel upconversion luminescence immunoassay and total cTnT with a commercial high-sensitivity cTnT assay in 24 TTS patients and in 84 Type 1 MI patients. The ratio of long to total cTnT (troponin ratio) was determined as a measure of cTnT fragmentation.
RESULTS RESULTS
Troponin ratio was lower in TTS patients 0.13 [0.10-0.20] vs. 0.62 [0.29-0.96], p<0.001). In the ROC curve analyses, troponin ratio showed a better predictive power than total cTnT in discriminating TTS and MI patients (AUC 0.869 [CI95% 0.789-0.948)] vs. 0.766 [CI95% 0.677-0.855], p=0.047). When restricting the analysis to patients with total cTnT below 1200 ng/L (maximal value in TTS patients), the respective AUC values for total cTnT and troponin ratio were 0.599 (CI 95% 0.465-0.732) and 0.816 (CI95% 0.712-0.921), p =0.003). At a cutoff point of 0.12, troponin ratio correctly identified 95% of MI patients and 50% of TTS patients.
CONCLUSIONS CONCLUSIONS
In contrast to Type 1 MI, only a small fraction of circulating cTnT in TTS exists in intact or long molecular forms. This clear difference in troponin composition could be of diagnostic value when evaluating patients with cTnT elevations and suspicion of TTS.
REGISTRATION BACKGROUND
URL: https://www.clinicaltrials.gov; Unique identifier: NCT04465591.

Identifiants

pubmed: 39422200
pii: 7826109
doi: 10.1093/ehjacc/zuae115
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT04465591']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.

Auteurs

K E Juhani Airaksinen (KEJ)

Heart Center, Turku University Hospital and University of Turku, Turku, Finland.

Tuulia Tuominen (T)

Biotechnology Unit, Department of Life technologies, University of Turku, Turku, Finland.

Tuomas Paana (T)

Heart Center, Turku University Hospital and University of Turku, Turku, Finland.

Tapio Hellman (T)

Kidney Center, Turku University Hospital and University of Turku, Turku, Finland.

Tuija Vasankari (T)

Heart Center, Turku University Hospital and University of Turku, Turku, Finland.

Selma Salonen (S)

Biotechnology Unit, Department of Life technologies, University of Turku, Turku, Finland.

Helea Junes (H)

Biotechnology Unit, Department of Life technologies, University of Turku, Turku, Finland.

Anna Linko-Parvinen (A)

TYKS laboratories, Clinical Chemistry, Turku University Hospital, Turku, Finland.
Department of Clinical Chemistry, University of Turku, Turku, Finland.

Hanna-Mari Pallari (HM)

TYKS laboratories, Clinical Chemistry, Turku University Hospital, Turku, Finland.

Marjatta Strandberg (M)

Emergency Care, Turku University Hospital, Turku, Finland.

Konsta Teppo (K)

Heart Center, Turku University Hospital and University of Turku, Turku, Finland.
Biotechnology Unit, Department of Life technologies, University of Turku, Turku, Finland.

Samuli Jaakkola (S)

Heart Center, Turku University Hospital and University of Turku, Turku, Finland.

Saara Wittfooth (S)

Biotechnology Unit, Department of Life technologies, University of Turku, Turku, Finland.

Classifications MeSH